LPTX Leap Therapeutics


Data from SEC filings
Employee count

Shareholder alignment

Proxy contests and exempt solicitations in last 3 years

No recent proxy contest or exempt solicitation filings from shareholders.

Vote support at last AGM

(a) Leap Therapeutics, Inc. (the “Company”) held its 2021 Annual Meeting of Stockholders (the “Annual Meeting”) on June 15, 2021.

(b) The final voting results on each of the matters submitted to a vote of stockholders at the Annual Meeting are set forth below.

(1) The following director nominees were elected to serve as Class I directors until the Company’s 2024 annual meeting of stockholders and until their successors are duly elected and qualified.

Nominee Votes For Votes Withheld Votes Abstaining Broker Non-Votes
Monica Bertagnolli, MD, FASCO32,934,6071,630,963010,633,884
James Cavanaugh, PhD32,695,6631,869,907010,633,884
Douglas E. Onsi32,887,7061,677,864010,633,884

(2) The appointment of EisnerAmper LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2021, was ratified.

Votes For Votes Against Votes Abstaining